Autres langues Solid Biosciences Inc.

Actions

SLDB

US83422E2046

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/06/2024			Varia. 5j.	Varia. 1 janv.
7,47 ^USD	-5,44%		-4,48%	+21,66%

11/06	Solid Biosciences Inc. annonce la démission de membres de son conseil d'administration	CI
15/05	Solid Biosciences Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Solid Biosciences Inc. Announces Board Resignations	11/06
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/06
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results	15/05
Solid Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting	07/05
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/05
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/04
Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label	01/04
Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne	01/04
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	01/04
Solid Biosciences Inc. Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	01/04
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium	27/03
North American Morning Briefing : Inflation -2-	15/03
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results	13/03
Solid Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD	07/03
Solid Biosciences Inc. Announces Licensing Agreement with Armatus Bio for the Use of Aav-Slb101, A Proprietary, Muscle-Targeted Capsid, in the Development of an Rnai Therapy to Treat Fshd	07/03
Solid Biosciences to Participate at Upcoming Investor Conferences	06/03
Solid Biosciences Gets FDA Orphan Drug Designation for Duchenne Drug Candidate	16/01
Solid Biosciences Gets Orphan Drug Designation for SGT-003	16/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Solid Biosciences Inc.

Actions

SLDB

US83422E2046

Autres langues

Filtres